



養和醫療  
HKSH MEDICAL GROUP

For Immediate Release

## HKSH Medical Group Marks a New Milestone in Liver Cancer Care with Li Ka Shing Foundation's Donation of Histotripsy 2.0 System

(29 April 2025, Hong Kong) HKSH Medical Group (HKSH) is pleased to announce the generous donation of the revolutionary Histotripsy 2.0 system by the Li Ka Shing Foundation (LKSF). This innovative, non-invasive liver cancer treatment, utilising high-intensity focused ultrasound to precisely target liver tumours, enhances HKSH's established capabilities in liver cancer care, offering patients even more targeted, comprehensive and personalised treatment options. Following meticulous preparations, specialised training, and rigorous clinical governance protocols, the dedicated team of HKSH Cancer Centre has launched the "Non-Invasive Liver Cancer Histotripsy Treatment Programme" with pre-treatment assessments began in mid-April, and the first Histotripsy procedure scheduled for early May, bringing more advanced treatment and disease management opportunities for liver cancer patients.

**Dr. Walton LI, Chief Executive Officer of HKSH Medical Group and Medical Superintendent of Hong Kong Sanatorium & Hospital**, said, "We sincerely thank the Li Ka Shing Foundation for its trust and support for HKSH, which reflects our shared commitment to advancing medical innovation in Hong Kong. HKSH has in place a robust array of comprehensive liver disease treatment options, including surgery, radiotherapy, thermal ablation, intra-arterial therapy, liver transplantation, targeted therapies and the introduction of the Greater Bay Area's first proton therapy system in 2023. Now with the Li Ka Shing Foundation's generous donation of the non-invasive liver cancer Histotripsy system, HKSH is equipped with a full spectrum of specialised liver disease treatment technologies, enabling our medical team to tailor the most appropriate, comprehensive, effective, and relatively lower-risk treatment plans based on each patient's unique conditions. Benefiting patients in Hong Kong, Asia, and the Greater China region has always been the mission of the Li Shu Fan Medical Foundation and HKSH."

**Mr. Li Ka-shing, Chairman of the Li Ka Shing Foundation**, having observed the Histotripsy 2.0 system for the first time ever said to Dr LI, "With such a good option, why not? HKSH providing this option is definitely a great news."

Data from the Hong Kong Cancer Registry indicates that liver cancer is the fifth most prevalent cancer in Hong Kong and the third leading cause of cancer-related mortality. In Mainland China, primary liver cancer is the second highest in both mortality figures and rates. Therefore, in addition to rigorous liver health monitoring, the development of advanced liver cancer treatment technologies is particularly crucial. **Dr LI** added, "Hong Kong is at the forefront in Asia for introducing the Histotripsy system, and HKSH is proud to be part of this significant milestone. HKSH has long been committed to leveraging cutting-edge equipment and training highly experienced medical professionals. We are confident that the introduction and widespread adoption of the Histotripsy system will further benefit cancer patients locally, across Asia, and beyond."

### Non-Invasive Liver Cancer Treatment to Pioneer Medical Innovation

The non-invasive Histotripsy represents a relatively lower-risk and highly effective breakthrough in liver cancer treatment, approved by the U.S. Food and Drug Administration and supported by evidence-based research for clinical use in treating primary or metastatic liver cancer. It is also a viable option for patients unsuitable for surgical intervention or those for whom other liver cancer treatments have been ineffective. The Histotripsy 2.0 system adopted by HKSH utilises high-intensity focused ultrasound to precisely target liver tumours, creating microbubbles within the tumour that rapidly expand and collapse, generating shockwaves that disrupt and liquefy the tumours. The entire procedure is guided by advanced real-time ultrasound imaging, ensuring precise targeting of the tumour while minimising impact on surrounding tissues, significantly reducing treatment side effects. As

養和醫療集團有限公司  
HKSH Medical Group Limited

香港跑馬地山村道2號  
2 Village Road, Happy Valley, Hong Kong

電話 Tel : (852) 2835 8800  
傳真 Fax : (852) 2835 8008  
電郵 Email : [medicalgroup@hksh.com](mailto:medicalgroup@hksh.com)



Members of HKSH Medical Group:  
Hong Kong Sanatorium & Hospital | HKSH Healthcare | HKSH Eastern Medical Centre | HKSH Cancer Centre

[www.hksh.com](http://www.hksh.com)



**養和醫療**  
HKSH MEDICAL GROUP

a non-invasive procedure, Histotripsy involves no radiation or thermal energy, allowing patients to undergo treatment with minimal discomfort and no surgical wounds. Most patients can be discharged the day following treatment based on medical advice.

### **Multidisciplinary Expertise and Advanced Technology to Achieve Precision Liver Cancer Treatment**

The dedicated Histotripsy Team at HKSH comprises multidisciplinary medical professionals, including specialists in clinical oncology, medical oncology, surgery, and radiology, who have completed professional training in Hong Kong and the United States. With the official launch of the non-invasive Histotripsy system, HKSH Cancer Centre is now equipped with state-of-the-art diagnostic and treatment technologies, offering comprehensive and advanced treatment options. These include surgery, thermal ablation, intra-arterial therapy (dual tracer PET/CT scanning combined with Yttrium-90 (Y-90) selective internal radiation therapy (SIRT) for advanced-stage liver cancer), proton therapy and stereotactic radiotherapy, immunotherapy, and targeted therapies. Regardless of a patient's eligibility for Histotripsy, the highly experienced medical team is committed to developing personalised, effective, and relatively lower-risk treatment plans tailored to each patient's needs.

To ensure that patients receive the most appropriate and relatively lower-risk treatment, all patients will initially undergo a comprehensive pre-treatment assessment at HKSH, including detailed ultrasound imaging and physical examinations. Only those deemed suitable patients will proceed to Histotripsy treatment. Both assessment and treatment procedures are offered under a package pricing scheme, providing patients with greater financial clarity when considering their options. In addition, eligible Hong Kong residents can enjoy a fee reduction for Histotripsy treatment, enabling more patients to benefit from this innovative therapy.

For enquiries or appointments regarding Histotripsy treatment, please contact HKSH Cancer Centre at (852) 5213 6365 (phone or WhatsApp), or visit HKSH website: <https://www.hksh.com/histotripsy/en/index.php>.

–END–

### **For media enquiries, please contact:**

Corporate Affairs Department

Carol KWOK                      Tel: 2917 5838  
Joyce CHAN                      Tel: 2917 5835

Email: [media@cad.hksh.com](mailto:media@cad.hksh.com)

### **About HKSH Medical Group**

Officially launched in September 2017, HKSH Medical Group, through its operating members, adopts a multi-faceted, coordinated approach to promote public health and advanced medicine through relentless efforts in clinical excellence, medical training and research as well as public health education. Members of the Group, including Hong Kong Sanatorium & Hospital, HKSH Healthcare, HKSH Eastern Medical Centre and HKSH Cancer Centre, are dedicated to offering top-quality holistic care to patients, upholding the motto 'Quality in Service, Excellence in Care.'

Established in 1922, Hong Kong Sanatorium & Hospital is one of the key members of HKSH Medical Group and a leading private hospital in Hong Kong. Living up to its motto of 'Quality in Service, Excellence in Care', the Hospital is committed to serving the public as well as promoting medical education and research.

養和醫療集團有限公司  
HKSH Medical Group Limited

香港跑馬地山村道2號  
2 Village Road, Happy Valley, Hong Kong

電話 Tel : (852) 2835 8800  
傳真 Fax : (852) 2835 8008  
電郵 Email : [medicalgroup@hksh.com](mailto:medicalgroup@hksh.com)



**Members of HKSH Medical Group:**

Hong Kong Sanatorium & Hospital | HKSH Healthcare | HKSH Eastern Medical Centre | HKSH Cancer Centre

[www.hksh.com](http://www.hksh.com)



養和醫療  
HKSH MEDICAL GROUP

### **About The Li Shu Fan Medical Foundation**

The Li Shu Fan Medical Foundation was inaugurated in March 1963 to promote and support medical education, research and charity in Hong Kong. Since its inception, the not-for-profit Foundation has also been a major driving force of the development and improvement of the Hong Kong Sanatorium & Hospital as well as the HKSH Medical Group in terms of medical research, educational activities and service improvement.

For more information about HKSH Medical Group, please visit <http://www.hksh.com>.

### **Video:**

HKSH Medical Group YouTube: <https://youtu.be/LaaE0oRXhJc>

### **Photo:**



Accompanied by Dr. Walton LI, Chief Executive Officer of HKSH Medical Group and Medical Superintendent of Hong Kong Sanatorium & Hospital (right in front row), Dr. Joseph CHAN, Chief Medical Officer of HKSH Medical Group and Deputy Medical Superintendent of Hong Kong Sanatorium & Hospital (5<sup>th</sup> from right in back row), and Dr. LAU Chor Chiu, Chief Medical Executive of HKSH Eastern Medical Centre and Assistant Medical Superintendent of Hong Kong Sanatorium & Hospital (4<sup>th</sup> from right in back row), Mr. Li Ka-shing, Chairman of the Li Ka Shing Foundation (left in front row), visited the Histotripsy 2.0 training and demonstration at the Hong Kong Sanatorium & Hospital to understand more about the clinical applications of the system. Dr. Thomas LEUNG, Honorary Consultant in Hepatology, Comprehensive Oncology Centre, HKSH Cancer Centre (3<sup>rd</sup> from left in back row), Dr. Jimmy YUEN, Honorary Consultant in Radiology (Diagnostic), HKSH Department of Diagnostic & Interventional Radiology (3<sup>rd</sup> from right in back row) and Dr. Matt Brown, Regional Director of Education at HistoSonics, Inc. (2<sup>nd</sup> from left in back row), explained the clinical arrangements and treatment procedures. Team members who have finished the training also joined the session.

養和醫療集團有限公司  
HKSH Medical Group Limited

香港跑馬地山村道2號  
2 Village Road, Happy Valley, Hong Kong

電話 Tel : (852) 2835 8800  
傳真 Fax : (852) 2835 8008  
電郵 Email : [medicalgroup@hksh.com](mailto:medicalgroup@hksh.com)



Members of HKSH Medical Group:

Hong Kong Sanatorium & Hospital | HKSH Healthcare | HKSH Eastern Medical Centre | HKSH Cancer Centre

[www.hksh.com](http://www.hksh.com)

## Histotripsy treatment plan



## 嶄新肝癌無創組織碎化技術


Revolutionary Non-Invasive Histotripsy Technology for Liver Cancer

無創組織碎化技術利用高強度聚焦超聲波精準射擊肝癌腫瘤，在腫瘤內形成的微氣泡會迅速膨脹及收縮，繼而產生衝擊波破壞及液化腫瘤，同時對周邊組織的影響輕微。

養和癌症中心提供全面及先進的肝癌治療選擇，即使患者不適合進行組織碎化技術，具有豐富經驗的醫護團隊也會為患者制定其他個人化、有效且安全的治療方案。

The non-invasive histotripsy utilises high-intensity focused ultrasound to precisely target liver tumours. This method creates microbubbles within the tumours that rapidly expand and collapse, generating shockwaves that disrupt and liquify the tumours while causing minimal impact on surrounding tissues.

HKSH Cancer Centre offers comprehensive and advanced treatment options for tackling liver cancer. If the patient is not suitable for histotripsy, the experienced medical team will tailor alternative, effective and safe cancer treatment plan to meet individual needs.



養和癌症中心服務熱線  
HKSH Cancer Centre Service Hotline  
**5213 6365**



了解更多



WhatsApp



微信客服



### 治療前評估計劃

Pre-treatment Assessment Package

套餐收費 Package Price **HK\$8,000**



由組織碎化技術專責醫生提供評估\*

Managed by dedicated histotripsy doctor\*



超聲波檢查\*

Ultrasound examination\*



身體檢查  
(驗血、靜電心电图、胸透X光)

Physical investigation  
(blood test, electrocardiogram, chest X-ray)

\*如患者經醫生評估後不適宜此療法，所需支付的費用合共HK\$2,000。

\*If patient is unsuitable for histotripsy after assessment, the fee payable for the assessment will be charged.

\*如經醫生評估後不適宜此療法，所需支付的費用合共HK\$2,000。

\*If patient is unsuitable for histotripsy after assessment, the fee payable for the assessment will be charged.

### 肝癌組織碎化 治療套餐計劃

Liver Cancer Histotripsy Package

套餐收費 Package Price **HK\$310,000**

香港居民收費 HK\$260,000  
For Hong Kong Residents



治療費用

Treatment charges



在院醫生費用

In-house doctor fees



麻醉費

Anaesthesia fee



普通房 (兩日一夜)

General ward room charges  
(2 Days 1 Night)



儀器設備費

Equipment and  
instrument charges



護理費

Nursing care charges



基本藥物、消耗品、物料費

Basic medication fee, consumables, and materials charges

養和癌症中心服務熱線  
HKSH Cancer Centre Service Hotline  
**5213 6365**



了解更多



WhatsApp



微信客服

For more details, please visit HKSH Histotripsy website at <https://www.hksh.com/histotripsy/en/index.php>.